Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects
Technical Report,01 Aug 2016,31 Aug 2017
University of Florida Gainesville United States
Pagination or Media Count:
The overall objective is to provide proof-of-principle that recombinant human relaxin rhRLX administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesisvasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated reproducible implementation of uniform cranial lesions of 1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ngml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice 50 .
- Medicine and Medical Research